Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | No clear evidence for benefit with addition of Rova-T to chemo for extensive SCLC

Ross Camidge • 28 Sep 2019
ESMO 2019
General Lung Cancer Small Cell Lung Cancer Antibodies Rovalpituzumab tesirine

Ross Camidge, MD, PhD, University of Colorado, Denver, CO, discusses the phase I study evaluating rovalpituzumab tesirine (ROVA-T) in the frontline treatment of patients with extensive-stage small-cell lung cancer (NCT02819999). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Ross Camidge

3:21
Hot topics in 2020: lung cancer
Ross Camidge • 26 Mar 2020
4:15
COVID-19 & treating patients with lung cancer
Ross Camidge • 26 Mar 2020
10:43
Updates in ALK+ NSCLC
Ross Camidge • 26 Mar 2020
1:30
Efficacy of lorlatinib in NSCLC post-second generation ALK TKI
Ross Camidge • 28 Sep 2019

Related Videos

0:37
STABLE-MATES: sublobar resection vs SAbR in high-risk patients with stage I NSCLC
Clive Peedell • 18 Apr 2024
0:44
BTOG 2024: networking highlights and insights
Clive Peedell • 18 Apr 2024
0:49
Ongoing trials in thoracic radiotherapy: evaluating current role and significance
Thomas Newsom-Davis • 18 Apr 2024
4:20
Insights from BTOG 2024: advancements in TNM Staging, systematic staging, & immunotherapy strategies
Thomas Newsom-Davis • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals